Brief: Transgene To Present New Positive Preliminary Phase I Clinical Data For TG4050

Transgene SA

08/04/2022 18:13

April 8 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE TO PRESENT NEW POSITIVE PRELIMINARY PHASE I
CLINICAL
DATA AT AACR 2022, REINFORCING POTENTIAL OF TG4050
    * EARLY SIGNS OF CLINICAL ACTIVITY WERE OBSERVED WITH
ENCOURAGING
ONGOING ANTI-TUMOR ACTIVITY IN FIRST PATIENTS UNDER NEOANTIGEN
VACCINE TREATMENT
    * MANUFACTURING TIME AND DRUG RELEASE WERE COMPATIBLE WITH
CLINICAL TREATMENT PROTOCOLS

Source text for Eikon:  ID:nBw4hfT1sa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))